NDATOPICALLOTION
Approved
Apr 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
6/8 — Strong
DUOBRII (halobetasol propionate and tazarotene) by Bausch + Lomb. Approved for retinoid [epc]. First approved in 2019.
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DUOBRII is a fixed-dose combination topical lotion containing halobetasol propionate (a potent corticosteroid) and tazarotene (a retinoid) approved in 2019 for plaque psoriasis. The combination leverages dual mechanisms—anti-inflammatory steroid activity and retinoid-mediated gene expression modulation—to treat inflammatory skin conditions. It represents a convenient single-agent alternative to sequential retinoid and corticosteroid therapy.
$0.927MPart D
Peak9.6 years to LOEDUOBRII is in peak commercial phase with modest claim volume (863 in 2023), indicating a niche but stable product requiring focused market development and specialist engagement.
Mechanism of Action
Pharmacologic Class:
Retinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Duobrii Treatment of Acne Keloidalis Nuchae (AKN)
Started Oct 2022
15 enrolled
Acne Keloidalis NuchaeAKN
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Started Nov 2020
22 enrolled
Palmoplantar PsoriasisPlaque Psoriasis
Career Relevance
DUOBRII offers career opportunity in specialty dermatology commercial roles focused on penetrating a niche, high-value psoriasis segment with strong patent protection and minimal direct competition. Working on this product emphasizes payer negotiation, dermatologist relationship-building, and lifecycle management in a stable, peak-phase product with 9+ years of exclusivity.
Worked on DUOBRII at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.